评价富血小板血浆在瘢痕性脱发中的抗炎潜能:一项系统综述。

IF 1.5 4区 医学 Q3 DERMATOLOGY Journal of Drugs in Dermatology Pub Date : 2024-12-01 DOI:10.36849/jdd.7813
Susie Suh, Minjun Park, Arash Babadjouni, Natasha Atanaskova Mesinkovska
{"title":"评价富血小板血浆在瘢痕性脱发中的抗炎潜能:一项系统综述。","authors":"Susie Suh, Minjun Park, Arash Babadjouni, Natasha Atanaskova Mesinkovska","doi":"10.36849/jdd.7813","DOIUrl":null,"url":null,"abstract":"<p><p>Scarring alopecia, also known as cicatricial alopecia, is a group of hair loss disorders characterized by inflammatory destruction of hair follicles, leading to hair loss and scar tissue formation. Treating scarring alopecia is challenging due to the irreversible damage caused by the inflammatory process. Consequently, early intervention targeting inflammation is crucial for improving prognosis.1 Recently, several reports have emerged supporting the use of platelet-rich plasma (PRP) as a non-conventional therapy for scarring alopecia, suggesting its potential benefits in mitigating inflammation and halting disease progression. While there is a growing body of evidence demonstrating the efficacy and safety of PRP in nonscarring alopecia, such as androgenetic alopecia (AGA) and alopecia areata (AA), there remains a scarcity of evidence regarding the clinical benefits of PRP in scarring alopecias.2-7 In this study, we conducted a literature review exploring the effectiveness and safety of PRP in treating scarring alopecia. Eleven studies describing PRP treatment outcomes were identified. Overall, PRP demonstrated a positive impact, slowing disease progression with reduced signs of inflammation and no reported adverse effects. However, it is important to note that the evidence supporting the utility of PRP in scarring alopecias is currently limited to case reports. Therefore, immunomodulatory therapies should remain the mainstay therapy for scarring alopecias until further investigations are warranted. J Drugs Dermatol. 2024;23(12):1076-1082. doi:10.36849/JDD.7813.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"23 12","pages":"1076-1082"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating Anti-Inflammatory Potential of Platelet-Rich Plasma in Scarring Alopecia: A Systematic Review.\",\"authors\":\"Susie Suh, Minjun Park, Arash Babadjouni, Natasha Atanaskova Mesinkovska\",\"doi\":\"10.36849/jdd.7813\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Scarring alopecia, also known as cicatricial alopecia, is a group of hair loss disorders characterized by inflammatory destruction of hair follicles, leading to hair loss and scar tissue formation. Treating scarring alopecia is challenging due to the irreversible damage caused by the inflammatory process. Consequently, early intervention targeting inflammation is crucial for improving prognosis.1 Recently, several reports have emerged supporting the use of platelet-rich plasma (PRP) as a non-conventional therapy for scarring alopecia, suggesting its potential benefits in mitigating inflammation and halting disease progression. While there is a growing body of evidence demonstrating the efficacy and safety of PRP in nonscarring alopecia, such as androgenetic alopecia (AGA) and alopecia areata (AA), there remains a scarcity of evidence regarding the clinical benefits of PRP in scarring alopecias.2-7 In this study, we conducted a literature review exploring the effectiveness and safety of PRP in treating scarring alopecia. Eleven studies describing PRP treatment outcomes were identified. Overall, PRP demonstrated a positive impact, slowing disease progression with reduced signs of inflammation and no reported adverse effects. However, it is important to note that the evidence supporting the utility of PRP in scarring alopecias is currently limited to case reports. Therefore, immunomodulatory therapies should remain the mainstay therapy for scarring alopecias until further investigations are warranted. J Drugs Dermatol. 2024;23(12):1076-1082. doi:10.36849/JDD.7813.</p>\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"23 12\",\"pages\":\"1076-1082\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/jdd.7813\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/jdd.7813","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

瘢痕性脱发,又称瘢痕性脱发,是一组以炎性破坏毛囊,导致脱发和瘢痕组织形成为特征的脱发疾病。由于炎症过程造成的不可逆损伤,治疗瘢痕性脱发是具有挑战性的。因此,针对炎症的早期干预对于改善预后至关重要最近,一些报道支持使用富血小板血浆(PRP)作为瘢痕性脱发的非传统治疗方法,表明其在减轻炎症和阻止疾病进展方面的潜在益处。虽然有越来越多的证据表明PRP在非瘢痕性脱发(如雄激素性脱发(AGA)和斑秃(AA))中的有效性和安全性,但关于PRP在瘢痕性脱发中的临床益处的证据仍然缺乏。2-7在本研究中,我们对PRP治疗瘢痕性脱发的有效性和安全性进行了文献综述。确定了11项描述PRP治疗结果的研究。总体而言,PRP显示出积极的影响,减缓疾病进展,减少炎症迹象,无不良反应报告。然而,值得注意的是,支持PRP治疗瘢痕性脱发的证据目前仅限于病例报告。因此,在进一步的研究得到保证之前,免疫调节疗法仍应是瘢痕性脱发的主要治疗方法。皮肤医学杂志,2024;23(12):1076-1082。doi: 10.36849 / JDD.7813。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluating Anti-Inflammatory Potential of Platelet-Rich Plasma in Scarring Alopecia: A Systematic Review.

Scarring alopecia, also known as cicatricial alopecia, is a group of hair loss disorders characterized by inflammatory destruction of hair follicles, leading to hair loss and scar tissue formation. Treating scarring alopecia is challenging due to the irreversible damage caused by the inflammatory process. Consequently, early intervention targeting inflammation is crucial for improving prognosis.1 Recently, several reports have emerged supporting the use of platelet-rich plasma (PRP) as a non-conventional therapy for scarring alopecia, suggesting its potential benefits in mitigating inflammation and halting disease progression. While there is a growing body of evidence demonstrating the efficacy and safety of PRP in nonscarring alopecia, such as androgenetic alopecia (AGA) and alopecia areata (AA), there remains a scarcity of evidence regarding the clinical benefits of PRP in scarring alopecias.2-7 In this study, we conducted a literature review exploring the effectiveness and safety of PRP in treating scarring alopecia. Eleven studies describing PRP treatment outcomes were identified. Overall, PRP demonstrated a positive impact, slowing disease progression with reduced signs of inflammation and no reported adverse effects. However, it is important to note that the evidence supporting the utility of PRP in scarring alopecias is currently limited to case reports. Therefore, immunomodulatory therapies should remain the mainstay therapy for scarring alopecias until further investigations are warranted. J Drugs Dermatol. 2024;23(12):1076-1082. doi:10.36849/JDD.7813.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.20
自引率
13.30%
发文量
289
审稿时长
3-6 weeks
期刊介绍: The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
期刊最新文献
Non-Surgical Correction of Dermatochalasis Using Microplasma. Keloidal Morphea: A Unique Variant of Morphea Presenting in a Black Female. Sunscreens: Mechanisms and Safety in Depth. The Future of Machine Learning Enabled Technologies for Hair Loss Treatment. Use of Upadacitinib in Refractory Behcet's Disease: Case Report and Systematic Literature Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1